account_id none on file
legal_name NRX Pharmaceuticals, Inc.
ticker NRXP
cik 1719406
domain nrxpharma.com
linkedin_company_url https://www.linkedin.com/company/nrx-pharma/
entry_point_account_id none on file
name NRX Pharmaceuticals Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 8 executives 6 family 0
why_nownone on file
callsnone on file
filings
The Company leases office space on a month-to-month basis. The rent expense for the three months ended June 30, 2026 and 2025 was less than $ 0.1 million, respectively.
filing / Aug 14, 2026 / receipt
The unaudited pro forma information does not give effect to the potential impact of current financial conditions, regulatory matters or any anticipated synergies, operating efficiencies or cost savings that may be associated with the acquisition.
filing / Aug 14, 2026 / receipt
West Palm Beach Lease (Third Party): On November 14, 2025, the Company entered into a sublease agreement with Third Party of office space located at West Palm Beach, Florida.
filing / Aug 14, 2026 / receipt
Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2026 in providing reasonable assurance of achieving the desired control objectives.
filing / Aug 14, 2026 / receipt
The Company leases office space on a month-to-month basis. The rent expense for the three months ended March 31, 2026 and 2025 was less than $ 0.1 million, respectively.
filing / May 15, 2026 / receipt
The unaudited pro forma information does not give effect to the potential impact of current financial conditions, regulatory matters or any anticipated synergies, operating efficiencies or cost savings that may be associated with the acquisition.
filing / May 15, 2026 / receipt
West Palm Beach Lease (Third Party): On November 14, 2025, the Company entered into a sublease agreement with Third Party of office space located at West Palm Beach, Florida.
filing / May 15, 2026 / receipt
Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2026 in providing reasonable assurance of achieving the desired control objectives.
filing / May 15, 2026 / receipt
executives
| Ira Strassberg | Chief Financial Officer | - | receipt |
| Joseph M. Casper | Chief Operating Officer | - | receipt |
| Richard Narido | Interim Chief Financial Officer | - | receipt |
| Robert Besthof | Interim Chief Executive Officer | - | receipt |
| Seth Van Voorhees | Chief Financial Officer | - | receipt |
| Stephen Willard | Chief Executive Officer | - | receipt |
familynone on file
upcoming
changes
| 2026-02-02 | Chief Operating Officer, appointed | sec_8k |
| 2023-09-14 | Interim Chief Financial Officer, appointed | sec_8k |
| 2022-07-28 | Chief Corporate Officer, departed | sec_8k |
| 2022-07-15 | Chief Executive Officer, appointed | sec_8k |
| 2022-06-08 | Chief Financial Officer, appointed | sec_8k |
| 2022-03-18 | Chief Financial Officer, appointed | sec_8k |
| 2022-03-09 | Interim Chief Executive Officer, appointed | sec_8k |
mcp_package_hint
slug nrx-pharmaceuticals-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$